Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study

Nat Rev Rheumatol. 2021 Apr;17(4):238-243. doi: 10.1038/s41584-021-00578-2. Epub 2021 Feb 15.


The concept of psoriatic arthritis (PsA) prevention is gaining increased interest owing to the physical limitation, poor quality of life and low remission rates that are achieved with current therapies for PsA. The psoriasis-to-PsA transition offers a unique opportunity to identify individuals at increased risk of developing PsA and to implement preventive strategies. However, identifying individuals at increased risk of developing PsA is challenging as there is no consensus on how this population should be defined. This Consensus Statement puts forward recommended terminology from the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) for defining specific subgroups of individuals during the preclinical and early clinical phases of PsA to be used in research studies. Following a three-round Delphi process, consensus was reached for three terms and definitions: 'increased risk for PsA', 'psoriasis with asymptomatic synovio-entheseal imaging abnormalities' and 'psoriasis with musculoskeletal symptoms not explained by other diagnosis'. These terms and their definitions will enable improved identification and standardization of study populations in clinical research. In the future, as increasing evidence emerges regarding the molecular and clinical features of the psoriasis-to-PsA continuum, these terms and definitions will be further refined and updated.

Publication types

  • Consensus Development Conference
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Arthritis, Psoriatic / diagnosis
  • Arthritis, Psoriatic / drug therapy*
  • Arthritis, Psoriatic / prevention & control*
  • Arthritis, Psoriatic / psychology
  • Consensus
  • Delphi Technique
  • Disabled Persons / psychology
  • Drug Evaluation, Preclinical / ethics*
  • Drug Evaluation, Preclinical / methods
  • Female
  • Humans
  • Male
  • Psoriasis / complications
  • Psoriasis / diagnosis
  • Psoriasis / epidemiology
  • Psoriasis / therapy*
  • Quality of Life
  • Risk Assessment
  • Terminology as Topic